Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor Pharmacokinetics in Renal Impairment
NCT03844555Phase 1Completed
- Sponsor
- Genfit
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of elafibranor in primary biliary cholangitis (PBC) and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Genfit. Primary endpoints: Area under the plasma concentration-time curve from dosing time to last measurement and Area under the plasma concentration-time curve from dosing time to infinity. Started Feb 2019; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03844555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844555.